Strong preclinical and clinical rationale supporting therapeutic efficacy
Resetting chronic pain at the source.Cy Biopharma
Cy Biopharma is leading the charge in developing a new class of small molecule therapies that address the root cause of chronic pain through central nervous system modulation.
Our mission is to deliver single-dose, durable treatments for pain conditions with few or no effective options, starting with rare and orphan indications where the need is urgent, and the impact is profound.
Scroll down to find out more.
A new era in pain therapeutics
Chronic pain, especially neuropathic pain syndromes, affects millions globally. These conditions often persist for years, severely diminishing quality of life. For many patients, today’s standard treatments fall short: expensive, invasive, short-lasting, or ineffective.
Despite the scale of the crisis, innovation has lagged. No FDA-approved therapies exist for some of the most debilitating forms of chronic pain. Cy Biopharma is here to change that.
Our breakthrough approach
We are the first company globally to develop a chronic pain therapy targeting the 5-HT2A serotonin receptor using a proprietary, naturally derived compound designed to reset maladaptive neural circuitry. Unlike conventional treatments, our lead program aims to interrupt the pain cycle at the neurological source, not just mask symptoms.
Orphan drug strategy designed for regulatory acceleration and exclusivity
Non-invasive and easily scalable delivery method
Single-dose administration with long-term durability
Our first target:
Rare pain conditions
Cy Biopharma
Why it matters?
We are advancing a treatment for a rare, underserved chronic pain disorder that causes severe post-traumatic pain with no approved therapies.
Our approach is positioned to meet Orphan Drug criteria, unlocking accelerated FDA pathways, market exclusivity, and potential reimbursement advantages.
Why it matters?
- 01
Chronic pain is a multi-billion-dollar unmet medical need
- 02
Our lead indication represents a high-impact commercial opportunity
- 03
Our therapeutic approach may extend to a broad range of pain-related conditions
- 04
Backed by a world-class team of scientists, physicians, and biotech operators
Multidisciplinary leadership team with deep expertise in neuroscience, clinical development, regulatory strategy, and biotech operations.
Cy Team
Together, we bring decades of experience in bringing novel therapeutics to market, from discovery through regulatory approval.
David Pyrce
CEO, serial entrepreneur and former CEO of neuroscience-based therapeutics company & Wall Street executive
Prof. Richard Langford FRCA, FFPMRCA
CMO, former President of British Pain Society & current practicing physician at The London Clinic
Eric Bouilloux MSc
COO, proven operational success in leading both FDA & EU drug product registrations
James Morrison LLB BCL
Patient advocate & Cy Biopharma Founder
The investment opportunity
Cy Biopharma
By investing now, you join us at a critical inflection point, with:
We are currently raising capital to fund our next clinical milestone. This round will support a proof-of-concept clinical trial for our lead program, with a clear roadmap toward a Phase 3 study.
By investing now, you join us at a critical inflection point, with:
- 01
A first-mover advantage
- 02
A highly de-risked clinical rationale
- 03
A well-defined path to market authorization
We’re not just developing drugs. We’re redefining what’s possible in pain medicine.